Product Data Sheet

ABT-263 (Navitoclax)

Catalog No. A10022

main product photo
ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). it maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.
Adooq's ABT-263 (Navitoclax) has been cited by 21 publications
  • Yibo Wen, .et al. , Ren Fail, 2023, Dec;45(1):2194440 PMID: 37154092
  • Rindert Missiaen, .et al. , Cell Metab, 2022, Aug 2;34(8):1151-1167 PMID: 35839757
  • Ashlyn Parkhurst, .et al. , Cell Death Dis, 2022, Apr 28;13(4):410 PMID: 35484114
  • Suzuki, Keiji, .et al. , Mutat Res Genet Toxicol Environ Mutagen, 2022, 876-877. 503448
  • Rotem Ben-Hamo, .et al. , Nat Commun, 2020, 11: 3296
  • Hua Xu, .et al. , Cancers (Basel), 2020, Apr; 12(4): 831 PMID: 32235588
  • Hiroki Akiyama, .et al. , Cancers, 2020, 12 (2) PMID: 32050632
  • Stephanie Ketterer, .et al. , Nat Commun, 2020, Oct 12;11(1):5133 PMID: 33046706
  • Makoto Koyama, .et al. , Int J Oncol, 2020, Sep 2 PMID: 32901840
  • Min Li, .et al. , Nat Commun, 2020, 11: 4051 PMID: 32792548
  • Hamzehlou S, .et al. , Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
  • Momeny M, .et al. , Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
  • Anderson R, .et al. , EMBO J, 2019, Feb 8. pii: e100492 PMID: 30737259
  • Shinya Ishida, .et al. , Oncotarget, 2018, Jun 1; 9(42): 26834-26851 PMID: 29928488
  • Rhys Anderson, .et al. , bioRxiv, 2018, 2018
  • Ryuta Mikawa, .et al. , Aging Cell, 2018, Oct; 17(5): e12827 PMID: 30058137
  • Joo Sang Lee, .et al. , Nat Commun, 2018, 9: 2546 PMID: 29959327
  • Toshiyuki Sumi, .et al. , Int J Oncol, 2018, Jul; 53(1): 33-46 PMID: 29658609
  • Wei TW, .et al. , Cancer Res, 2017, Jan 15;77(2):494-508 PMID: 28069801
  • Yusuke Takagi, .et al. , Cancer Sci, 2016, Sep; 107(9): 1270-1280 PMID: 27348272
  • Matsumoto M, .et al. , Biochem Biophys Res Commun, 2016, Apr 29;473(2):490-6 PMID: 26996126
  • Chemical Information
    Catalog Num A10022
    M. Wt 974.6
    Formula C47H55ClF3N5O6S3
    Purity >98%
    Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
    CAS No. 923564-51-6
    Synonyms ABT263
    SMILES CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
    Storage

    Store lyophilized at -20ºC, keep desiccated.
    In lyophilized form, the chemical is stable for 36 months.
    In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Biological Activity
    Discription
    ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). it maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.
    Targets
    Target Value
    Solubility
    In vitro (25°C) DMSO 89 mg/mL (91.31 mM)
    Water Insoluble
    Ethanol Insoluble
    In vivo 5% DMSO+corn oil 6 mg/mL
    * <1 mg/ml means slightly soluble or insoluble.
    * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
    Preparing Stock Solutions
    Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
    0.1 mM 10.26 mL 51.3 mL 102.61 mL
    0.5 mM 2.05 mL 10.26 mL 20.52 mL
    1 mM 1.03 mL 5.13 mL 10.26 mL
    5 mM 0.21 mL 1.03 mL 2.05 mL
    RETURN POLICY
    Adooq’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
    SHIPPING AND STORAGE
    Adooq products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Adooq Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Adooq products are stable under the recommended conditions.